NEUROONE MEDICAL TECHNOLOGIES Corp
Financial highlights
| Metric | FY 09/30/25 | FY 09/30/24 | FY 09/30/23 | FY 09/30/22 | FY 09/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.1M | $3.5M | $2.0M | $171,169 | $178,146 |
| Cost of revenue | $4.0M | $2.4M | $1.5M | $241,963 | $275,895 |
| Gross profit | $5.1M | $1.1M | $456,517 | -$70,794 | -$97,749 |
| Selling, general & administrative | $7.4M | $7.9M | $6.9M | $7.0M | $6.3M |
| Research and development | $5.0M | $5.1M | $6.9M | $4.9M | $3.9M |
| Operating expenses | $12.4M | $13.0M | $13.9M | $11.9M | $10.2M |
| Operating income | -$4.2M | -$11.9M | -$12.0M | -$10.0M | -$10.2M |
| Interest expense | — | — | — | — | $3,053 |
| Pretax income | -$3.6M | -$12.3M | -$11.9M | -$10.0M | — |
| Income tax expense | — | — | — | — | -$271,122 |
| Net income | -$3.6M | -$12.3M | -$11.9M | -$10.0M | -$9.9M |
| Balance Sheet | |||||
| Cash and equivalents | $6.6M | $1.5M | $5.3M | $8.2M | $6.9M |
| Current assets | $10.2M | $4.6M | $7.3M | $12.2M | $7.3M |
| Total assets | $10.8M | $5.4M | $8.1M | $12.8M | $7.9M |
| Current liabilities | $2.3M | $2.2M | $1.8M | $3.1M | $1.2M |
| Total liabilities | $3.7M | $4.5M | $1.8M | $3.2M | $1.4M |
| Stockholders' equity | $7.1M | $822,013 | $6.2M | $9.6M | $6.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$2.8M | -$11.0M | -$12.9M | -$7.5M | -$8.6M |
| Depreciation and amortization | $239,363 | $224,476 | $199,266 | $118,620 | $80,748 |
| Stock-based compensation | $1.3M | $1.3M | $1.1M | $947,212 | $1.8M |
| Capital expenditure | $81,742 | $120,197 | $384,117 | $275,226 | $67,079 |
| Free cash flow | -$2.9M | -$11.1M | -$13.3M | -$7.8M | -$8.7M |
| Share repurchases | $124,617 | $81,403 | $119,419 | — | — |
Shares outstanding 8.6M · Free float 79.4%
Annual filing data through FY ended September 30, 2025; float as of July 4, 2026.